A Point Mutation at C151 of Keap1 of Mice Abrogates NRF2 Signaling, Cytoprotection in Vitro, and Hepatoprotection in Vivo by Bardoxolone Methyl (CDDO-Me)

Bardoxolone methyl (CDDO-Me) is an oleanane triterpenoid in late-stage clinical development for the treatment of patients with diabetic kidney disease. Preclinical studies in rodents demonstrate the efficacy of triterpenoids against carcinogenesis and other diseases, including renal ischemia-reperfu...

Descripción completa

Detalles Bibliográficos
Autores principales: Gatbonton-Schwager, Tonibelle, Yagishita, Yoko, Joshi, Tanvi, Wakabayashi, Nobunao, Srinivasan, Harini, Suzuki, Takafumi, Yamamoto, Masayuki, Kensler, Thomas W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Pharmacology and Experimental Therapeutics 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353147/
https://www.ncbi.nlm.nih.gov/pubmed/37188495
http://dx.doi.org/10.1124/molpharm.123.000671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353147/
https://www.ncbi.nlm.nih.gov/pubmed/37188495
http://dx.doi.org/10.1124/molpharm.123.000671

Ejemplares similares